ATC Group: C01DX Other vasodilators used in cardiac diseases

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01DX in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C01 Cardiac therapy
3 C01D Vasodilators used in cardiac diseases
4 C01DX Other vasodilators used in cardiac diseases

Group C01DX contents

Code Title
C01DX01 Itramin tosilate
C01DX02 Prenylamine
C01DX03 Oxyfedrine
C01DX04 Benziodarone
C01DX05 Carbocromen
C01DX06 Hexobendine
C01DX07 Etafenone
C01DX08 Heptaminol
C01DX09 Imolamine
C01DX10 Dilazep
C01DX11 Trapidil
C01DX12 Molsidomine
C01DX13 Efloxate
C01DX14 Cinepazet
C01DX15 Cloridarol
C01DX16 Nicorandil
C01DX18 Linsidomine
C01DX19 Nesiritide
C01DX22
C01DX51 Itramin tosilate, combinations
C01DX52 Prenylamine, combinations
C01DX53 Oxyfedrine, combinations
C01DX54 Benziodarone, combinations

Active ingredients in C01DX

Active Ingredient Description
Dilazep
Heptaminol
Molsidomine

Molsidomine is a long acting vasodilating drug. Molsidomine, a sydnonimine acting as a heterocyclic direct nitric oxide donor, has been used for the treatment of patients with stable angina pectoris. It’s also established drug for the treatment of coronary heart disease. Molsidomine is metabolized in the liver to the active metabolite linsidomine. Linsidomine is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.

Nicorandil

Nicorandil is a derivative of the niacinamide that is structurally combined with an organic nitrate. It provides a dual mode of action leading to relaxation of vascular smooth muscle. Nicorandil is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase. Nicorandil has a direct effect on coronary arteries without leading to a steal phenomenon. The overall action improves blood flow to post-stenotic regions and the oxygen balance in the myocardium.

Trapidil
Vericiguat

Vericiguat is a stimulator of soluble guanylate cyclase (sGC). Heart failure is associated with impaired synthesis of nitric oxide (NO) and decreased activity of its receptor, sGC. The pharmacodynamic effects of vericiguat are consistent with the mode of action of a sGC stimulator resulting in smooth muscle relaxation and vasodilation.

Related product monographs

Title Information Source Document Type  
IKOREL Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VERQUVO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC